PCSK9 and atherosclerosis: It is likely that the positive results of the FOURIER trial and the subsequent positive results of the ODYSSEY OUTCOMES trial [3] with alirocumab, the publication of recommendations from national professional organizations, and the price reduction explain the increased prescribing of PCSK9 inhibitors in our cohort of patients with ASCVD.